drugset / Trial / NCT00591266

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

NCT00591266

Phase 3 Completed 566 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.

Timeline

Start
2007-10
Primary completion
2009-03
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral
Background Amlodipine Other / unclassified 5 mg Oral